HK1175112A1 - Combination cancer therapy with hsp90 inhibitory compounds hsp90 - Google Patents

Combination cancer therapy with hsp90 inhibitory compounds hsp90

Info

Publication number: HK1175112A1
Authority: HK; Hong Kong
Prior art keywords: hsp90; cancer therapy; inhibitory compounds; combination cancer; combination
Prior art date: 2009-10-19

Application number

HK13102428.3A

Other languages

English (en)

Chinese (zh)

Inventor

Ronald K Blackman

Kevin Paul Foley

David Proia

Original Assignee

Synta Pharmaceuticals Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-19

Filing date

2013-02-26

Publication date

2013-06-28

2013-02-26 Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp

2013-06-28 Publication of HK1175112A1 publication Critical patent/HK1175112A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HK13102428.3A 2009-10-19 2013-02-26 Combination cancer therapy with hsp90 inhibitory compounds hsp90 HK1175112A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US27933009P	2009-10-19	2009-10-19
US33577810P	2010-01-11	2010-01-11
PCT/US2010/053199 WO2011049946A1 (en)	2009-10-19	2010-10-19	Combination cancer therapy with hsp90 inhibitory compounds

Publications (1)

Publication Number	Publication Date
HK1175112A1 true HK1175112A1 (en)	2013-06-28

Family

ID=43218142

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK13102428.3A HK1175112A1 (en)	2009-10-19	2013-02-26	Combination cancer therapy with hsp90 inhibitory compounds hsp90

Country Status (22)

Country	Link
US (1)	US20120245186A1 (xx)
EP (1)	EP2490688B1 (xx)
JP (2)	JP2013508378A (xx)
KR (1)	KR20120093970A (xx)
CN (1)	CN102695504A (xx)
AU (1)	AU2010308306A1 (xx)
BR (1)	BR112012009215A2 (xx)
CA (1)	CA2779233A1 (xx)
CY (1)	CY1115902T1 (xx)
DK (1)	DK2490688T3 (xx)
EA (1)	EA022119B1 (xx)
ES (1)	ES2526566T3 (xx)
HK (1)	HK1175112A1 (xx)
HR (1)	HRP20141150T1 (xx)
MX (1)	MX2012004577A (xx)
NZ (2)	NZ599445A (xx)
PH (1)	PH12012500748A1 (xx)
PL (1)	PL2490688T3 (xx)
PT (1)	PT2490688E (xx)
RS (1)	RS53716B1 (xx)
SI (1)	SI2490688T1 (xx)
WO (1)	WO2011049946A1 (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007021966A1 (en)	2005-08-12	2007-02-22	Synta Pharmaceuticals Corp.	Pyrazole compounds that modulate hsp90 activity
US20070250391A1 (en) *	2006-04-05	2007-10-25	Prade Hendrik D	Merchandising system and method for food and non-food items for a meal kit
WO2007139967A2 (en)	2006-05-25	2007-12-06	Synta Pharmaceuticals Corp.	Triazole compounds that modulate hsp90 activity
US8063083B2 (en)	2006-05-25	2011-11-22	Synta Pharmaceuticals Corp.	Method for treating non-Hodgkin's lymphoma
AU2007267843B2 (en)	2006-05-25	2011-10-13	Synta Pharmaceuticals Corp.	Method for treating proliferative disorders associated with protooncogene products
US9156836B2 (en) *	2008-05-16	2015-10-13	Synta Pharmaceuticals Corp.	Tricyclic triazole compounds that modulate HSP90 activity
US8450500B2 (en)	2008-06-04	2013-05-28	Synta Pharmaceuticals Corp.	Pyrrole compounds that modulate HSP90 activity
DK2328893T3 (da) *	2008-08-08	2013-06-17	Synta Pharmaceuticals Corp	Triazolforbindelser som modulerer hsp90 aktivitet
WO2010017545A2 (en)	2008-08-08	2010-02-11	Synta Pharamceuticals Corp.	Triazole compounds that modulate hsp90 activity
BR112012018631A8 (pt)	2010-01-28	2017-12-19	President And Fellows Of Harvard Colege	composições e métodos para intensificação da atividade do proteassoma
EP2560640A1 (en)	2010-04-19	2013-02-27	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2011146803A1 (en) *	2010-05-20	2011-11-24	Synta Pharmaceuticals Corp.	Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
US20130172333A1 (en) *	2010-05-20	2013-07-04	Synta Pharmaceuticals Corp.	Formulation and dosing of hsp90 inhibitory compounds
US20130171105A1 (en) *	2010-05-24	2013-07-04	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
JP2013537229A (ja) *	2010-09-13	2013-09-30	シンタファーマシューティカルズコーポレーション	野生型ｅｇｆｒ及び／又はｋｒａｓ患者において非小細胞肺癌を処置するためのｈｓｐ９０阻害剤
TR201906779T4 (tr)	2011-05-12	2019-05-21	Proteostasis Therapeutics Inc	Proteostaz regülatörleri.
US20140228418A1 (en) *	2011-05-23	2014-08-14	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitory compounds with mek inhibitors
US20140315943A1 (en) *	2011-05-24	2014-10-23	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
EP2714033A1 (en) *	2011-05-26	2014-04-09	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitory compounds with chk inhibitors
JP2014520808A (ja)	2011-07-07	2014-08-25	シンタファーマシューティカルズコーポレーション	Ｈｓｐ９０阻害化合物を用いた癌の治療
EP2776025A1 (en) *	2011-11-02	2014-09-17	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013067162A1 (en) *	2011-11-02	2013-05-10	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
EP2780010A1 (en) *	2011-11-14	2014-09-24	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with braf inhibitors
US9849135B2 (en)	2013-01-25	2017-12-26	President And Fellows Of Harvard College	USP14 inhibitors for treating or preventing viral infections
KR20160104612A (ko)	2013-07-26	2016-09-05	업데이트 파마 인코포레이트	비산트렌의 치료 효과 개선용 조성물
WO2015073528A1 (en)	2013-11-12	2015-05-21	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
SG11201700779RA (en)	2014-08-04	2017-02-27	Nuevolution As	Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
AU2016301188A1 (en)	2015-08-06	2018-02-15	Chimerix, Inc.	Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
CN105237533B (zh) *	2015-10-26	2017-03-22	中国药科大学	四氢吡啶并[4,3‑d]嘧啶类Hsp90抑制剂及其医药用途
WO2019060692A1 (en)	2017-09-21	2019-03-28	Chimerix, Inc.	MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES
WO2021124277A1 (en)	2019-12-20	2021-06-24	Nuevolution A/S	Compounds active towards nuclear receptors
CA3174176A1 (en)	2020-03-31	2021-10-07	Sanne Schroder Glad	Compounds active towards nuclear receptors
WO2021198955A1 (en)	2020-03-31	2021-10-07	Nuevolution A/S	Compounds active towards nuclear receptors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6274171B1 (en)	1996-03-25	2001-08-14	American Home Products Corporation	Extended release formulation of venlafaxine hydrochloride
EP2295416B1 (en)	2004-11-18	2016-01-27	Synta Pharmaceuticals Corp.	Triazole compounds that modulate HSP90 activity
AU2007267843B2 (en) *	2006-05-25	2011-10-13	Synta Pharmaceuticals Corp.	Method for treating proliferative disorders associated with protooncogene products
DE102007002715A1 (de) *	2007-01-18	2008-07-24	Merck Patent Gmbh	Triazolderivat
CA2680161A1 (en) *	2007-03-05	2008-09-12	Kyowa Hakko Kirin Co., Ltd.	Pharmaceutical composition
WO2009002321A1 (en)	2007-06-27	2008-12-31	Thomson Licensing	Enhancing image quality
CN101801983B (zh) *	2007-08-13	2014-01-29	辛塔制药公司	调控hsp90活性的三唑化合物
JP2014520808A (ja) *	2011-07-07	2014-08-25	シンタファーマシューティカルズコーポレーション	Ｈｓｐ９０阻害化合物を用いた癌の治療

2010
- 2010-10-19 CA CA2779233A patent/CA2779233A1/en not_active Abandoned
- 2010-10-19 BR BR112012009215A patent/BR112012009215A2/pt not_active IP Right Cessation
- 2010-10-19 PT PT107683575T patent/PT2490688E/pt unknown
- 2010-10-19 JP JP2012535301A patent/JP2013508378A/ja not_active Ceased
- 2010-10-19 ES ES10768357.5T patent/ES2526566T3/es active Active
- 2010-10-19 NZ NZ599445A patent/NZ599445A/en not_active IP Right Cessation
- 2010-10-19 US US13/501,608 patent/US20120245186A1/en not_active Abandoned
- 2010-10-19 EP EP10768357.5A patent/EP2490688B1/en active Active
- 2010-10-19 RS RS20140705A patent/RS53716B1/en unknown
- 2010-10-19 PH PH1/2012/500748A patent/PH12012500748A1/en unknown
- 2010-10-19 PL PL10768357T patent/PL2490688T3/pl unknown
- 2010-10-19 SI SI201030832T patent/SI2490688T1/sl unknown
- 2010-10-19 EA EA201270570A patent/EA022119B1/ru not_active IP Right Cessation
- 2010-10-19 DK DK10768357.5T patent/DK2490688T3/en active
- 2010-10-19 KR KR1020127012977A patent/KR20120093970A/ko not_active Ceased
- 2010-10-19 AU AU2010308306A patent/AU2010308306A1/en not_active Abandoned
- 2010-10-19 CN CN201080056689XA patent/CN102695504A/zh active Pending
- 2010-10-19 MX MX2012004577A patent/MX2012004577A/es active IP Right Grant
- 2010-10-19 NZ NZ622713A patent/NZ622713A/en not_active IP Right Cessation
- 2010-10-19 WO PCT/US2010/053199 patent/WO2011049946A1/en active Application Filing
2013
- 2013-02-26 HK HK13102428.3A patent/HK1175112A1/xx not_active IP Right Cessation
2014
- 2014-11-26 HR HRP20141150AT patent/HRP20141150T1/hr unknown
- 2014-12-31 CY CY20141101097T patent/CY1115902T1/el unknown
2015
- 2015-10-08 JP JP2015199844A patent/JP2016041715A/ja active Pending

Also Published As

Publication number	Publication date
JP2016041715A (ja)	2016-03-31
EP2490688B1 (en)	2014-10-08
CA2779233A1 (en)	2011-04-28
MX2012004577A (es)	2012-06-13
EP2490688A1 (en)	2012-08-29
BR112012009215A2 (pt)	2019-09-24
KR20120093970A (ko)	2012-08-23
ES2526566T3 (es)	2015-01-13
RS53716B1 (en)	2015-04-30
CY1115902T1 (el)	2017-01-25
NZ622713A (en)	2015-07-31
US20120245186A1 (en)	2012-09-27
WO2011049946A1 (en)	2011-04-28
NZ599445A (en)	2014-04-30
PH12012500748A1 (en)	2012-10-29
EA201270570A1 (ru)	2012-09-28
HRP20141150T1 (hr)	2015-01-30
DK2490688T3 (en)	2014-12-08
JP2013508378A (ja)	2013-03-07
AU2010308306A1 (en)	2012-05-10
SI2490688T1 (sl)	2015-01-30
EA022119B1 (ru)	2015-11-30
PL2490688T3 (pl)	2015-03-31
CN102695504A (zh)	2012-09-26
PT2490688E (pt)	2014-12-29

Publication	Publication Date	Title
HK1175112A1 (en)	2013-06-28	Combination cancer therapy with hsp90 inhibitory compounds hsp90
HK1175476A1 (en)	2013-07-05	Cancer treatment
PL2482849T3 (pl)	2018-11-30	Skojarzona immunoterapia w leczeniu nowotworu
IL206654A0 (en)	2010-12-30	Combination therapy
PT2303021T (pt)	2019-04-01	Compostos para tratamento do cancro
IL215764A0 (en)	2012-01-31	Adjuvant cancer therapy
IL199992A0 (en)	2010-04-15	Combination therapy
IL213761A0 (en)	2011-07-31	Novel ortho-aminoamides for the treatment of cancer
IL222958A0 (en)	2013-02-03	Cancer treatment
IL210066A0 (en)	2011-02-28	Novel ortho-aminoanilides for the treatment of cancer
EP2585115A4 (en)	2014-12-17	CANCER THERAPY
EP2288702A4 (en)	2011-06-29	COMBINATION THERAPIES AGAINST CANCER
EP2211863A4 (en)	2012-07-25	COMBINATION THERAPY
EP2403341A4 (en)	2012-10-24	LUNGENKREBSBEHNDLUNG
GB0700284D0 (en)	2007-02-14	Combination therapy
EP2473613A4 (en)	2013-02-27	KREBSAUSHUNGERUNGSTHERAPIE
GB0916997D0 (en)	2009-11-11	Combination therapy
GB0803948D0 (en)	2008-04-09	Combination therapy
GB0907973D0 (en)	2009-06-24	Combination therapy
GB0809046D0 (en)	2008-06-25	Cancer treatment
GB0906026D0 (en)	2009-05-20	Therapeutic compounds
GB0913603D0 (en)	2009-09-16	Cancer therapy
GB0921102D0 (en)	2010-01-13	Cancer Therapy
GB2470001A9 (en)	2010-12-22	The reason of all cancer types
AU2009901405A0 (en)	2009-04-23	Cancer therapy

Legal Events

Date	Code	Title	Description
2019-05-31	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20181022